The U.S. electrophysiology mapping and ablation devices market size was estimated at USD 10.47 billion in 2024 and is projected to reach USD 23.11 billion by 2033, growing at a CAGR of 8.05% from 2025 to 2033. Widespread use of electrophysiology (EP) mapping and ablation devices in the U.S. is being driven by the escalating burden of atrial fibrillation and other complex arrhythmias, particularly among aging and at-risk populations.
As clinical guidelines increasingly favor early interventional treatment, hospitals and ambulatory centers are expanding their EP capabilities.Rising obesity rates, hypertension, and diabetes prevalence in the U.S. are contributing to increased procedure volumes and accelerating the demand for advanced diagnostic and therapeutic EP technologies. According to the CDC, approximately 12.1 million people in the U.S. will be suffering from atrial fibrillation by 2030. The growing burden of arrhythmias in the U.S., particularly atrial fibrillation, is driving increased adoption of electrophysiology (EP) mapping and ablation devices.
As hospitals and specialty centers expand their cardiac programs, there is a rising demand for tools that enable faster, more accurate diagnosis and targeted treatment. In March 202, Clinical Cardiology published a 25-year analysis of arrhythmia-related deaths in the U.S., reporting 5.05 million deaths among adults aged 35+ from 1999-2023. Mortality fell from 1999 to 2009, then rose steadily, peaking in 2021 during the COVID-19 pandemic before declining slightly.
Technological advancement remains a key driver of market growth. Innovations in 3D mapping systems, pulsed field ablation platforms, and AI-guided navigation are improving precision and reducing procedural risk. These technologies are gaining traction among U.S. providers seeking to streamline workflows, enhance outcomes, and stay ahead in an increasingly competitive electrophysiology landscape. In June 2025, Phillips Medisize launched TheraVolt, its first branded line of medical connectors tailored for high-voltage, high pin-count electrophysiology (EP) mapping and ablation devices. Designed to support pulsed field ablation therapies, TheraVolt offers customizable, sterilization-compatible solutions with high-density integration and platform flexibility.
Growing awareness and screening initiatives across the U.S. are accelerating the use of EP technologies. Community health programs, health system-led outreach, and proactive rhythm monitoring are helping identify arrhythmias earlier. As more patients are diagnosed before complications arise, demand for diagnostic and therapeutic EP procedures and the devices that support them continues to rise. In July 2025, a white paper published by PCNA evaluated the outcomes of a community-based screening initiative targeting atrial fibrillation (AFib) and hypertension in Baltimore, Maryland. The report noted that AFib remains underdiagnosed due to its episodic symptoms, underscoring the growing need for early, minimally invasive diagnostic solutions as cases are projected to rise to 12.1 million by 2030.
This product will be delivered within 2 business days.
As clinical guidelines increasingly favor early interventional treatment, hospitals and ambulatory centers are expanding their EP capabilities.Rising obesity rates, hypertension, and diabetes prevalence in the U.S. are contributing to increased procedure volumes and accelerating the demand for advanced diagnostic and therapeutic EP technologies. According to the CDC, approximately 12.1 million people in the U.S. will be suffering from atrial fibrillation by 2030. The growing burden of arrhythmias in the U.S., particularly atrial fibrillation, is driving increased adoption of electrophysiology (EP) mapping and ablation devices.
As hospitals and specialty centers expand their cardiac programs, there is a rising demand for tools that enable faster, more accurate diagnosis and targeted treatment. In March 202, Clinical Cardiology published a 25-year analysis of arrhythmia-related deaths in the U.S., reporting 5.05 million deaths among adults aged 35+ from 1999-2023. Mortality fell from 1999 to 2009, then rose steadily, peaking in 2021 during the COVID-19 pandemic before declining slightly.
Technological advancement remains a key driver of market growth. Innovations in 3D mapping systems, pulsed field ablation platforms, and AI-guided navigation are improving precision and reducing procedural risk. These technologies are gaining traction among U.S. providers seeking to streamline workflows, enhance outcomes, and stay ahead in an increasingly competitive electrophysiology landscape. In June 2025, Phillips Medisize launched TheraVolt, its first branded line of medical connectors tailored for high-voltage, high pin-count electrophysiology (EP) mapping and ablation devices. Designed to support pulsed field ablation therapies, TheraVolt offers customizable, sterilization-compatible solutions with high-density integration and platform flexibility.
Growing awareness and screening initiatives across the U.S. are accelerating the use of EP technologies. Community health programs, health system-led outreach, and proactive rhythm monitoring are helping identify arrhythmias earlier. As more patients are diagnosed before complications arise, demand for diagnostic and therapeutic EP procedures and the devices that support them continues to rise. In July 2025, a white paper published by PCNA evaluated the outcomes of a community-based screening initiative targeting atrial fibrillation (AFib) and hypertension in Baltimore, Maryland. The report noted that AFib remains underdiagnosed due to its episodic symptoms, underscoring the growing need for early, minimally invasive diagnostic solutions as cases are projected to rise to 12.1 million by 2030.
U.S. Electrophysiology Mapping And Ablation Devices Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. electrophysiology mapping and ablation devices market report based on procedure type and product coverage:Procedure Type Outlook (Revenue, USD Million, 2021 - 2033)
- EP Ablation Procedures
- By Indication
- Atrial Fibrillation
- Paroxysmal AF
- Persistent AF
- Long standing persistent/permanent
- Right Atrial Flutter
- Left Atrial Flutter
- Atrioventricular Nodal Reentry Tachycardia (AVNRT)
- Right Atrial Tachycardia (AT)
- Left Atrial Tachycardia (AT)
- Right Wolff-Parkinson-White (WPW)
- Left Wolff-Parkinson-White (WPW)
- Right Ventricular Tachycardia (VT)
- Left Ventricular Tachycardia (VT)
- Stand-Alone EP Diagnostic Procedures
- By Product Type
- Focal Ablation Catheter
- Radiofrequency (RF)
- Conventional
- Irrigated-tip
- Contact-Force-Sensing
- Standard
- Alternative Energy
- Pulsed Field Ablation
- Balloon Ablation Catheters
Product Coverage Outlook (Revenue, USD Million, 2021 - 2033)
- Mapping & Lab Systems
- X-Ray Systems
- Mapping Systems
- EP Recording Systems
- ICE Systems
- RF Ablation Generators
- Pulsed Field Ablation Generators
- Cryoablation Generators
- Diagnostic Catheters
- Conventional
- Fixed
- Steerable
- Advanced
- Ultrasound
- Ablation Catheters
- Focal Ablation Catheter
- Radiofrequency (RF)
- Conventional
- Irrigated-tip
- Contact-Force-Sensing
- Standard
- Alternative Energy
- Pulsed Field Ablation
- Balloon Ablation Catheters
- Accessory Devices
- Long Introducer Sheaths
- Fixed
- Steerable
- Transseptal Needles
- Conventional
- RF
- Navigational Accessories
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Electrophysiology Mapping and Ablation Devices Market Variables, Trends & Scope
Chapter 4. U.S. Electrophysiology Mapping and Ablation Devices Market: Procedure Type Estimates & Trend Analysis
Chapter 5. U.S. Electrophysiology Mapping and Ablation Devices Market: Product Coverage Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Siemens Healthineers
- Koninklijke Philips N.V.
- Abbott
- Johnson & Johnson (Biosense Webster)
- GE HealthCare
- Boston Scientific Corporation
- Medtronic
- Biotronik SE & Co KG
- MicroPort Scientific Corporation
- CardioFocus, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | July 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 10.47 Billion |
| Forecasted Market Value ( USD | $ 23.11 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | United States |
| No. of Companies Mentioned | 10 |
